October, the company announced that it is withdrawing the financial targets communicated on 1 June 2022. The targets are currently under revision ...

Nine-Point-Seven Percent CAGR Reflects Fundamental Industry Shift Toward Advanced LC-MS/MS and High-Resolution Platforms ...

According to multiple recent market analyses, the global API market is experiencing steady growth. One comprehensive forecast ...

The pharmaceutical industry operates under an uncompromising mandate: zero defects. Every tablet, capsule, vial, or syringe ...

Ipsen Delivers Strong Results In 2025, Driven By Solid Execution Across All Therapeutic Areas, And Provides 2026 Guidance. <li /> FY 2025 sales growth of 10.9% at CER1, or 8.1% as reported, driven by ...

The Health Ministry proposes draft amendments to remove provisional registration for ethics committees, aiming to streamline ...

FY 2025 sales growth of 10.9% at CER1, or 8.1% as reported, driven by growth of the three therapeutic areas of Oncology (4.1%1), Rare Disease (102.5%1) and Neuroscience (9.7%1); Somatuline sales growt ...

Now, Chinese pharmaceutical company Shanghai Shiling Pharmaceutical has announced it is trialing a semaglutide nasal spray, ...

Is Trump's Healthcare Agenda Being Undermined by FDA ...

From the limited roll-out of a new HIV prevention jab, to new weight-loss medicines, to high-stakes court cases relating to ...

New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and ...

To lower health care costs, the Trump administration will have to wrangle a complex system fraught with competing interests.